Inspire Medical Systems Inc. Common Stock (INSP)
Stock · NYSE · Health Care
$68.79as of 10/16/2026
Price chart
Active signals
INSP Signal Track Record
How signals performed across all stocks →What INSP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -1.7% | 41% | October 1, 2026 |
| Bollinger Band Breakout | 22 | +1.2% | 55% | September 9, 2026 |
| Bollinger Band Breakdown | 21 | -4.1% | 33% | May 5, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.5% | 46% | September 9, 2026 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loo…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 1,333
- Website
- www.inspiresleep.com/
Fundamentals
- 1-day range
- $71.43$78.8
- Market cap
- $1.70B
- P/E (trailing)
- 15.06
- P/E (forward)
- 49.95
- EPS (trailing)
- $4.61
- Dividend yield
- —
- Beta
- 0.66
- Avg. volume
- 870.6K
How Inspire Medical Systems Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Inspire Medical Systems Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INSPInspire Medical Systems Inc. Common Stock$68.79▼ 1.90%Market cap $1.70BP/E 15.06$38.91$147.03
- NVCRNovoCure Limited Ordinary Shares$14.07▼ 2.36%Market cap $1.83BP/E —$9.82$21.45
- LMATLeMaitre Vascular Inc. Common Stock$80.82▼ 2.81%Market cap $1.85BP/E 29.17$78.22$118.01
- KMTSKestra Medical Technologies Ltd. Common Stock$27.24▼ 5.02%Market cap $1.48BP/E —$17.34$30
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INSP Inspire Medical Systems Inc. Common Stock | $1.70B | 15.06 | $68.79 | ▼ 1.90% | $38.91$147.03 |
| NVCR NovoCure Limited Ordinary Shares | $1.83B | — | $14.07 | ▼ 2.36% | $9.82$21.45 |
| LMAT LeMaitre Vascular Inc. Common Stock | $1.85B | 29.17 | $80.82 | ▼ 2.81% | $78.22$118.01 |
| KMTS Kestra Medical Technologies Ltd. Common Stock | $1.48B | — | $27.24 | ▼ 5.02% | $17.34$30 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Waters Launches BD FACSDiscover A7 for Advanced Flow CytometryYahoo · 9/18/2026
- Reasons to Add West Pharmaceutical Stock to Your Portfolio NowYahoo · 9/18/2026
- Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for NowYahoo · 9/17/2026
- Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEXYahoo · 9/17/2026
- Here's Why You Should Retain CONMED Stock in Your Portfolio for NowYahoo · 9/16/2026
- GEHC Launches CareIntellect AI Tool to Optimize Hospital OperationsYahoo · 9/16/2026
- Inspire Medical Systems (INSP) Stock Could Be 14% Undervalued On Cash FlowYahoo · 9/15/2026
- Zacks Industry Outlook Medical Systems, American Well and Butterfly NetworkYahoo · 9/14/2026
Insider Activity
Insider Actions →- Kelly Jason P · August 7, 2026 · Sale963 @ $59.55
- Mann Melissa · July 31, 2026 · Tax Withholding326 @ $50.21
- CARREL MICHAEL H · July 20, 2026 · Grant5.6K
- Melenikiotou Georgia · July 15, 2026 · Grant344
- Casey M. Tansey · July 15, 2026 · Grant346
- Broader Shelley G · July 15, 2026 · Grant383
- Gary Lee Ellis · July 15, 2026 · Grant581
- Rondoni John · May 15, 2026 · Sale2.6K @ $43.28
- Rondoni John · May 14, 2026 · Sale700 @ $43.01
- mcCormick Shawn · May 8, 2026 · Sale696 @ $45.31
- Melenikiotou Georgia · May 1, 2026 · Tax Withholding50 @ $56.7
- Myriam Curet · April 30, 2026 · Grant3.6K
- Burks Cynthia · April 30, 2026 · Grant3.6K
- Melenikiotou Georgia · April 30, 2026 · Grant3.6K
- Casey M. Tansey · April 30, 2026 · Grant3.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 33.33M
- Total value held
- $1.67B
- Institutional holders
- 295
- Unknown3.55M
- Unknown2.70M
- Unknown2.54M
- Unknown1.45M
- Unknown1.27M
- Unknown1.20M
- Unknown1.14M
- Unknown956.0K
- Unknown780.6K
- Unknown677.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.